Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Alternative to prophylactic pancreatic stent placement in high-risk ERCP? 

This month's issue of the American Journal of Gastroenterology exmines the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP?

News image

A recent large-scale randomized controlled trial demonstrated that rectal indomethacin administration is effective in addition to pancreatic stent placement for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk cases.

Dr Joseph Elmunzer from Michigan, USA performed a post hoc analysis of this randomized controlled trial to explore whether rectal indomethacin can replace PSP in the prevention of pancreatitis and to estimate the potential cost savings of such an approach.

The team retrospectively classified randomized controlled trial subjects into 4 prevention groups.

Group 1 included no prophylaxis, Group 2 involved pancreatic stent placement alone, Group 3 received rectal indomethacin alone, and Group 4 included the combination of pancreatic stent placement and indomethacin.

Multivariable logistic regression was used to adjust for imbalances in the prevalence of risk factors for pancreatitis between the groups.

Based on these adjusted pancreatitis rates, the research team conducted an economic analysis comparing the costs associated with pancreatitis prevention strategies employing rectal indomethacin alone, pancreatic stent placement alone, or the combination of both.

A prevention strategy employing rectal indomethacin alone could save about $150 million annually
American Journal  of  Gastroenterology

ogyAfter adjusting for risk using 2 different logistic regression models, rectal indomethacin alone appeared to be more effective for preventing  pancreatitis than no prophylaxis, pancreatic stent placement alone, and the combination of indomethacin and pancreatic stent placement .

The doctors found that indomethacin alone was a cost-saving strategy in 96% of Monte Carlo trials.

A prevention strategy employing rectal indomethacin alone could save approximately $150 million annually in the United States compared with a strategy of pancreatic stent placement alone, and $85 million compared with a strategy of indomethacin and pancreatic stent placement.

Dr Joseph's team commented, "This hypothesis-generating study suggests that prophylactic rectal indomethacin could replace pancreatic stent placement  in patients undergoing high-risk preventing post-endoscopic retrograde cholangiopancreatography, potentially improving clinical outcomes and reducing healthcare costs."

"A randomized controlled trial comparing rectal indomethacin alone vs indomethacin plus pancreatic stent placement is needed."

Am J Gastroenterol 2013; 108: 410415
21 March 2013

Go to top of page Email this page Email this page to a colleague

 01 September 2015

Advanced search
 01 September 2015 
Nonceliac wheat sensitivity and autoimmune disease
 01 September 2015 
Dysphagia after antireflux surgery
 01 September 2015 
Predict treatment success in ulcerative colitis
 31 August 2015 
Cancer incidence in Barrett's
 31 August 2015 

Fecal microbiota transplantation in IBD

 31 August 2015 
Probiotics and liver transplantation
 28 August 2015 
Statin use and survival in pancreatic cancer
 28 August 2015 
Bacterial endotoxin and NAFLD
 28 August 2015 
Interferon-free regimens for Hep C
 27 August 2015 
HCV in Egypt
 27 August 2015 
Gene expression for hepatocellular carcinoma
 27 August 2015 
Liver abnormalities in celiac disease
 26 August 2015 
Medical management of diverticular disease
 26 August 2015 
Treatment of erosive esophagitis
 26 August 2015 
Dermatological complications of anti-TNF therapy in IBD
 25 August 2015 
Markers for colorectal cancer screening
 25 August 2015 
Long-term PPI use and serum gastrin levels
 25 August 2015 
Treatment for HCV and HIV-1 co-infection
 24 August 2015 
Treatment for HCV and HIV-1 co-infection
 24 August 2015 
Cirrhosis in Hepatitis C patients
 24 August 2015 
Aspirin use and colorectal cancer survival
 21 August 2015 
Activity indexes in ulcerative colitis
 21 August 2015 
Coffee and gallstone disease
 21 August 2015 
Alcoholic cirrhosis in relapse after liver transplant
 20 August 2015 
Cirrhosis in the USA
 20 August 2015 
Mortality causes in liver cirrhosis
 20 August 2015 
Risk of death in IBD
 19 August 2015 
Predicting intestinal surgery in Crohn's disease
 19 August 2015 
Sleep positioning device reduces reflux
 19 August 2015 
Improved screening colonoscopy quality
 18 August 2015 
Health insurance influences HCV screening outcomes
 18 August 2015 
Somatostatin analogues in polycystic liver disease
 18 August 2015 
Global consensus report on H. pylori gastritis
 17 August 2015 
Biomarker of fibrosis stage in NAFLD
 17 August 2015 
Prognostic score for primary biliary cirrhosis
 17 August 2015 
Measuring subjective health in patients with IBS
 14 August 2015 
Factors that influence ulcerative colitis procedure type
 14 August 2015 
H. pylori in African American and Hispanic veterans
 14 August 2015 
Hep E virus in decompensated chronic liver disease
 13 August 2015 
H. pylori in drinking water
 13 August 2015 
Sofosbuvir-regimens in HCV
 13 August 2015 
IBS among Japanese adolescents
 12 August 2015 
Infliximab in patients in IBD
 12 August 2015 
Predictors of severity of IBD
 12 August 2015 
Peritoneal carcinomatosis in colorectal cancer
 11 August 2015 
Chemotherapy and intestinal microbiomes
 11 August 2015 
H. pylori and immune thrombocytopenic purpura
 11 August 2015 
Sexual dysfunction after rectal cancer treatment
 10 August 2015 
Predicting lymph node metastasis in T1 colorectal cancer
 10 August 2015 
Scoring systems to predict alcoholic hepatitis outcomes
 10 August 2015 
Sofosbuvir-based regimens in veterans with HCV
 07 August 2015 
Factors associated with changes in ulcerative colitis
 07 August 2015 
Bariatric surgery and NASH in obese patients
 07 August 2015 
Caffeine and fibrosis in Hep C
 06 August 2015 
Disparities in colonoscopic examination
 06 August 2015 
Weight loss and NASH
 06 August 2015 
Diagnosis of IBS
 05 August 2015 
Gender differences in fecal immunochemical tests
 05 August 2015 
Adenoma detection rates with a screening colonoscopy program
 05 August 2015 
Extraintestinal manifestations in IBD diagnosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us